Tigermed Reports 14% Revenue Growth in 2026 Interim Results

The company’s growth was driven by a strong performance in its clinical trial solutions segment, which generated RMB 1.77 billion, alongside its lab and clinical-related services. Domestic revenue in China surged by 24%, while overseas operations contributed RMB 1.6 billion. As of June 30, 2026, Tigermed managed 667 ongoing drug clinical research projects and expanded its global footprint, notably increasing its U.S. clinical trial portfolio by 45%.

Strategic expansion remained a priority during the reporting period, marked by the completion of acquisitions including Teddy Laboratory and Shanghai Bioquick. These moves aim to solidify the firm's integrated R&D capabilities from preclinical testing to clinical supply chains. Additionally, the company inaugurated its new global headquarters and park in Hangzhou. Tigermed continues to lean into digital transformation, deploying AI-driven clinical research platforms and expanding its decentralized clinical trial (DCT) offerings, which secured over RMB 300 million in new orders during the half-year period.